[go: up one dir, main page]

WO2008087123A3 - Utilisation d'antagonistes de 5-ht6 pour empêcher une récidive d'addiction - Google Patents

Utilisation d'antagonistes de 5-ht6 pour empêcher une récidive d'addiction Download PDF

Info

Publication number
WO2008087123A3
WO2008087123A3 PCT/EP2008/050360 EP2008050360W WO2008087123A3 WO 2008087123 A3 WO2008087123 A3 WO 2008087123A3 EP 2008050360 W EP2008050360 W EP 2008050360W WO 2008087123 A3 WO2008087123 A3 WO 2008087123A3
Authority
WO
WIPO (PCT)
Prior art keywords
addiction
relapse
antagonists
compounds
prevent relapse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/050360
Other languages
English (en)
Other versions
WO2008087123A2 (fr
Inventor
Bruin Natasja M W J De
Loevezijn Arnold Van
Johan Wijnen
Arnoldus H J Herremans
Cornelis G Kruse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Publication of WO2008087123A2 publication Critical patent/WO2008087123A2/fr
Publication of WO2008087123A3 publication Critical patent/WO2008087123A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur une nouvelle utilisation de composés et de sels pharmaceutiquement acceptables de ceux-ci, qui sont des antagonistes de 5-HT6. Ces composés sont utiles pour la préparation de médicaments de prévention d'une récidive d'addiction, en particulier une récidive d'addiction à l'usage de substances toxiques (opiacés, hallucinogènes, produits pour inhalation, phencyclidine, amphétamines, cocaïne, cannabis, nicotine et alcool) ainsi qu'à certains médicaments (sédatifs, hypnotiques et anxiolytiques), et de prévention d'une rechute dans certains comportements addictifs comme le jeu.
PCT/EP2008/050360 2007-01-16 2008-01-15 Utilisation d'antagonistes de 5-ht6 pour empêcher une récidive d'addiction Ceased WO2008087123A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88042107P 2007-01-16 2007-01-16
EP07100576.3 2007-01-16
EP07100576 2007-01-16
US60/880,421 2007-01-16

Publications (2)

Publication Number Publication Date
WO2008087123A2 WO2008087123A2 (fr) 2008-07-24
WO2008087123A3 true WO2008087123A3 (fr) 2008-11-27

Family

ID=39574309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/050360 Ceased WO2008087123A2 (fr) 2007-01-16 2008-01-15 Utilisation d'antagonistes de 5-ht6 pour empêcher une récidive d'addiction

Country Status (1)

Country Link
WO (1) WO2008087123A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428334B (zh) * 2006-09-22 2014-03-01 Abbvie Bahamas Ltd 作為５-ｈｔ6拮抗劑之磺醯基吡唑及磺醯基吡唑啉的甲脒衍生物
MX2011011519A (es) 2009-04-30 2012-01-30 Abbott Gmbh & Co Kg Compuestos de bencensulfonanilida adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
US8362010B2 (en) 2009-04-30 2013-01-29 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
CN102459197B (zh) 2009-04-30 2015-08-19 Abbvie公司 适用于治疗响应血清素5-ht6受体的调节的病症的n-苯基-(哌嗪基或高哌嗪基)-苯磺酰胺或苯磺酰基-苯基-(哌嗪或高哌嗪)化合物
AU2013239995A1 (en) * 2012-03-27 2014-11-06 Albany Medical College Blocking of cue-induced drug reinstatement
CA3012900A1 (fr) * 2016-02-05 2017-08-10 Pharnext Nouvelles therapies combinees contre les troubles neurologiques
WO2025220005A1 (fr) * 2024-04-15 2025-10-23 Hadasit Medical Research Services And Development Ltd. Composés et leurs utilisations en tant que modulateurs des récepteurs de la sérotonine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072548A1 (fr) * 2002-02-22 2003-09-04 Pharmacia & Upjohn Company Derives de pyridyl sulfone utilises comme antagonistes du recepteur 5-ht
WO2003072558A2 (fr) * 2002-02-22 2003-09-04 Pharmacia & Upjohn Company Derives d'arylsulfone
WO2003099797A1 (fr) * 2002-05-23 2003-12-04 Pharmacia & Upjohn Company Sels de bis-arylsulfones destines au traitement de troubles du systeme nerveux central
WO2004009600A1 (fr) * 2002-07-18 2004-01-29 Wyeth 1-heterocyclylalkyl-3-sulfonylazaindole ou derives d'-azaindazole utilises en tant que ligands de 5-hydroxytryptamine-6
WO2005066157A1 (fr) * 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrrolidine-3-l)indoles en tant que modulateurs du recepteur 5-ht6
WO2007147883A1 (fr) * 2006-06-23 2007-12-27 Laboratorios Del Dr. Esteve, S.A. Combinaison d'un inhibiteur de la cholinestérase et d'un composé ayant une affinité envers le récepteur 5-ht6

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072548A1 (fr) * 2002-02-22 2003-09-04 Pharmacia & Upjohn Company Derives de pyridyl sulfone utilises comme antagonistes du recepteur 5-ht
WO2003072558A2 (fr) * 2002-02-22 2003-09-04 Pharmacia & Upjohn Company Derives d'arylsulfone
WO2003099797A1 (fr) * 2002-05-23 2003-12-04 Pharmacia & Upjohn Company Sels de bis-arylsulfones destines au traitement de troubles du systeme nerveux central
WO2004009600A1 (fr) * 2002-07-18 2004-01-29 Wyeth 1-heterocyclylalkyl-3-sulfonylazaindole ou derives d'-azaindazole utilises en tant que ligands de 5-hydroxytryptamine-6
WO2005066157A1 (fr) * 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrrolidine-3-l)indoles en tant que modulateurs du recepteur 5-ht6
WO2007147883A1 (fr) * 2006-06-23 2007-12-27 Laboratorios Del Dr. Esteve, S.A. Combinaison d'un inhibiteur de la cholinestérase et d'un composé ayant une affinité envers le récepteur 5-ht6

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MITCHELL, ELLEN S. ET AL: "BGC20-761, a novel tryptamine analog, enhances memory consolidation and reverses scopolamine-induced memory deficit in social and visuospatial memory tasks through a 5-HT6 receptor-mediated mechanism", NEUROPHARMACOLOGY , 50(4), 412-420 CODEN: NEPHBW; ISSN: 0028-3908, 2006, XP005287695 *

Also Published As

Publication number Publication date
WO2008087123A2 (fr) 2008-07-24

Similar Documents

Publication Publication Date Title
WO2008087123A3 (fr) Utilisation d'antagonistes de 5-ht6 pour empêcher une récidive d'addiction
WO2007013975A3 (fr) Compositions et procedes destines a controler l'abus de medicaments
IL193762A (en) The effective compounds in inhibiting dgat1-related disorders, their medicinal products and their use in the preparation of drugs
ZA200705879B (en) CGRP antagonists, method for production thereof, and their use as medicaments
IL205220A0 (en) 8 - [4 - (1 - AMINOCYCLOBUTYL)PHENYL]-9- PHENYL [1,2,4] TRIAZOLO [3,4-f]- 1,6 - NAPHTHYRIDINS AND THEIR USE FOR THE PREPARATION OF A MEDICAMENT FOR TREATING CANCER
IL181524A (en) Heterocyclic compounds, pharmaceuticals containing them and their use in the preparation of drugs
WO2008085765A3 (fr) Formes dosifiées de petit volume de médicament contenant du sufentanil s'administrant par voie trans-muqueuse orale pour le traitement de la douleur
WO2008002905A3 (fr) Formes galéniques solides du valsartan, de l'amlodipine et de l'hydrochlorothiazide et leur méthode de fabrication
IL221795B (en) Use of a pharmaceutical preparation of methylnaltrexone or a salt thereof for the preparation of a medicine for the treatment of side effects of treatment with opiates
IL228017A0 (en) Quinazolinone derivatives donated at position 5 as anti-cancer agents
WO2007022494A3 (fr) Conjugues de ligand multi medicament
DK1897545T3 (da) Manupulationsmodstandsdygtige orale, farmaceutiske doseringsformer indeholdende et opioidanalgetikum
IL198753A0 (en) Oral transmucosal nicotine dosage form
IL192591A0 (en) Edg-1 antagonists, processes for their manufacture, pharmaceutical compositions containing them and their use in the manufacture of medicaments and as medicaments for the production of an anti-cancer effect in a warm-blooded animal
IL190423A0 (en) Selected cgrp antagonists , methods for the production thereof and their use as medicaments
FR2909867B3 (fr) Capsule remplie d'un medicament, en particulier d'un medicament inhalable.
WO2006119884A3 (fr) Methode de traitement de la toxicomanie
CL2007002218A1 (es) Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
IL197232A (en) Carboxamidine derivatives of sulfonylpyrazole and sulfonylpyrazoline, drugs containing them, uses and processes for their preparation
IL201730A (en) History 1h - Benzaimidazole – 2 – Il – Profile – Methyl – Amino – Ethyl – 5 – Aryl – Bicyclo [2.2.2] Oct – 5 – Ann – 2 – All, Pharmaceutical preparations containing them and their use in the preparation of drugs
IL189497A0 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
SG10201500028RA (en) Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
WO2010006267A3 (fr) Tétrapeptides cycliques
WO2007116297A3 (fr) Utilisation d'aminaphtone pour la préparation d'un médicament destiné au traitement d'artériopathies
IL177456A0 (en) Substituted azetidine compounds, their preparation and use as medicaments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08701472

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08701472

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)